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complement is tightly controlled by a number of fluid-phase and cell surface proteins to avoid injury to
autologous tissues. When complement is hyperactivated, as occurs in autoimmune diseases or in subjects
with dysfunctional regulatory proteins, it drives a severe inflammatory response in numerous organs. The
kidney appears to be particularly vulnerable to complement-mediated inflammatory injury. Injury may derive
from deposition of circulating active complement fragments in glomeruli, but complement locally produced and
activated in the kidney also may have a role. Many kidney disorders have been linked to abnormal
complement activation, including immune-complex–mediated glomerulonephritis and rare genetic kidney
diseases, but also tubulointerstitial injury associated with progressive proteinuric diseases or ischemia-
reperfusion.
Semin Nephrol 33:479-492 C 2013 Elsevier Inc. All rights reserved.
Keywords: Complement, kidney, complement regulators, innate immunity, adaptive immunity, kidney
diseasesThe complement system is an important compo-nent of the innate immunity that functionsprimarily as a ﬁrst-line host defense against
pathogenetic infections.1,2 More than 30 components
and regulators have been identiﬁed that are widely
distributed in the circulation and in tissues, where they
are synthesized and secreted by a number of cells under
various stimuli, including cytokines and hormones.
Despite the lack of speciﬁcity that characterizes the
components of the acquired immune system, comple-
ment recognizes selectively foreign pathogens and
damaged self cells, using the recognition molecules
of the classic, lectin, and alternative pathways (Fig. 1).
Activated complement generates three major types
of effectors: (1) anaphylatoxins (C3a and C5a), which
are potent proinﬂammatory molecules that attract and
activate leukocytes through interaction with their
cognate G-protein–coupled receptors, C3a receptor
(C3aR) and C5a receptor (C5aR); (2) opsonins (C3b,
iC3b, and C3d), which decorate target surfaces through
covalent bonding to facilitate transport and favor
removal of target cells or immune complexes; and
(3) the terminal membrane attack complex (MAC,see front matter
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ephrology, Vol 33, No 6, November 2013, pp 479–492C5b-9) that directly lyses targeted (opsonized) patho-
gens or damaged self cells (Table 1). These effectors
allow the complement system to play an important role
in host defense against bacteria, and in the removal of
immune complexes and apoptotic cells, as indicated by
the ﬁnding that individuals with inherited and acquired
complement deﬁciencies are susceptible to bacterial
infections and immune complex diseases.3 Over the
past few years, other important functions of comple-
ment have been disclosed, including regulation of the
adaptive immune response, promotion of tissue regen-
eration and angiogenesis, mobilization of stem cells,
proper development of the central nervous system, and
control of embryo implantation.4
Unfortunately, the effector function of the system is
not focused solely on the targets to be neutralized, but
also may involve bystander cells. The end results
depend on the extent and the persistence of the
activation process. The undesired effects of complement
activation are controlled by several complement regu-
lators acting at different steps of the cascade and these
are present in the ﬂuid phase as well as on the surface of
tissue and circulating cells.5 However, unrestricted
complement activation easily can overcome the protec-
tion of the complement regulators and may result in
extensive host tissue damage. This situation often is
encountered in acute pathologic conditions, such as
sepsis or ischemia-reperfusion, or in chronic diseases
sustained and ampliﬁed by complement, activated by
immune complexes, an ongoing inﬂammatory process,
and/or by apoptotic/necrotic cells.
Among the human diseases that have been linked to
complement dysregulation, several disorders of the
kidney have been identiﬁed and studied extensively
both clinically and experimentally. These studies not
only have provided insights into the pathogenesis of
many kidney diseases, but also have contributed479
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Figure 1. Schematic overview of the complement cascade illustrating the three activation pathways (classical,
lectin, and alternative) and the MAC.
M. Noris and G. Remuzzi480signiﬁcantly to our understanding of complement-
mediated human tissue injury in general.
THE THREE COMPLEMENT ACTIVATION PATHWAYS
Three main pathways can activate the complement
system: classical, lectin, and alternative (Fig. 1). The
classical pathway (CP) uses C1 and is triggered by
antigen–antibody immune complexes. Inactive C1
circulates as a serum molecular complex comprising
six C1q molecules and two molecules each of theTable 1. The Main Physiologic Activities of the Complement System
Activity Compl
Host defense against infection
Oponization Covalently bound fragment
Chemotaxis and activation of
leukocytes
Anaphylatoxins (C5a, C3a)
Lysis of bacteria and cells Membrane-attack complex
Interface between innate and
adaptive immunity
Augmentation of antibody
response
C3b and C4b and their frag
receptors on B cells and
Enhancement of T-cell response
to APC
C3a and C5a, C3aR and C
Reduction of Treg function C3a and C5a, C3aR and C
Disposal of waste
Clearance of immune complexes
from tissues
C1q; covalently bound frag
receptors on phagocytes
Clearance of apoptotic cells C1q; covalently bound frag
receptors on phagocytes
Abbreviations: APC, antigen presenting cells; Treg, regulatory T ceserine proteases C1r and C1s. After binding to a
cognate antigen, the fragment crystallizable (Fc) por-
tion of an IgG or IgM antibody interacts with the
collagen-like tail of C1q. This interaction leads to a
conformational change resulting in the sequential
activation of C1r and C1s. The activated C1s then
cleaves C4 and C2 into small inactive fragments (C4a
and C2b) and larger active fragments (C4b and C2a).
C4b binds to the sugar moieties of cell surface
glycoproteins and binds noncovalently to C2a, to
generate the classic pathway C3 convertase C4bC2aement Protein Responsible for the Activity
s of C3 and C4 (C3b, C4b)
; anaphylatoxin receptors on leukocytes (C5aR, C3aR)
(C5b-9)
ments bound to immune complexes and to antigens; CR1-4
APC
5aR on T cells and APC
5aR on T cells and APC
ments of C3 (C3b) and C4 (C4b), CR1 on erythrocytes, CR1-4
ments of C3 (C3b) and C4 (C4b), CR1 on erythrocytes, CR1-4
lls.
Complement activation and regulation 481(Fig. 1). C4bC2a is an enzymatic complex that cleaves
C3, the central component of the complement cascade,
into the anaphylatoxin C3a and C3b. In addition to
activation by IgG and IgM immune complexes, C1q
also may be activated by apoptotic and necrotic cells
and by acute phase proteins such as C-reactive protein.6
The lectin pathway (LP) resembles the CP in that its
activation also leads to formation of the C4bC2a C3
convertase complex (Fig. 1). However, instead of
relying on antibodies to recognize pathogenic compo-
nents, the LP uses members of the collectin family of
plasma proteins, namely mannose-binding lectins
(MBLs) and ﬁcolins, to identify patterns of carbohy-
drate ligands that are found on the surface of a wide
variety of microorganisms. MBL consists of up to six
trimeric subunits whose structure resembles a bouquet-
like shape similar to that of C1q.1 The plasma concen-
tration of MBL can vary up to 1000-fold in normal
individuals. This variation largely is explained by
single-nucleotide polymorphisms within exon 1 of the
MBL-2 gene. Polymorphisms of the promoter region
contribute further to the variation in MBL levels.7
Ficolins are homologous to MBL. Binding of MBL
or ﬁcolins to distinct sugar molecules on the pathogenic
surface leads to activation of MBL-associated serine
proteases (MASP-1, MASP-2 and MASP-3), which
cleave C4 and C2 and generate C4bC2a in a reaction
analogous to the classic pathway (Fig. 1).
Although the classical and lectin pathways generally
are activated upon recognition of exogenous materials,
the alternative pathway (AP) is constitutively active at
low levels in the normal host. This often is referred to
as the tickover mechanism and allows the system to
stay primed for rapid and robust activation (Fig. 1).
Spontaneous hydrolysis of a thioester bond within C3
is thought to initiate the AP (Fig. 2). This leads to a
conformational change in the structure of C3, resulting
in a form of C3, referred to as C3(H2O), that functions
similar to C3b with regard to its ability to bind factor B
(CFB). The bound CFB then becomes a substrate for
the serine protease factor D (CFD). Cleavage of CFB
by CFD results in formation of the initiation AP C3
convertase C3(H2O)Bb, which, similar to the classic
C3 convertase C4bC2a, can cleave C3 into C3a and
C3b. The generation of C3b allows the AP to be fully
activated either in ﬂuid phase (ﬂuid phase C3b) or on
activating surfaces (surface bound C3b; Fig. 2) via
formation of the ampliﬁcation loop AP C3 convertase
C3bBb (Figs. 1 and 2).
It should be noted that although the spontaneously
generated C3(H2O)Bb is unique to AP, the C3b frag-
ment generated from any of the pathways can bind to
CFB and, with the participation of CFD, can form the
AP C3 convertase C3bBb, which serves as an ampli-
ﬁcation loop for the entire complement system by
rapidly augmenting the conversion of C3 to C3bnecessary for full activation of the system and its
downstream effects (Fig. 1).8 Newly formed C3bBb is
stabilized by the plasma protein properdin that binds to
the complex and slows its deactivation.8 Evidence also
is available that properdin, in addition to serving as a
stabilizer of AP C3 convertase, may initiate AP
activation by interacting with surface AP C3 conver-
tase or microbial antigens.9 Another notable ﬁnding of
recent studies is the requirement of MASP1/3 for
normal AP complement activity. Indeed, it has been
shown that MASP1/3 cleave inactive CFD zymogen
into the active form of CFD that normally is present in
plasma. When MASP-1/3 are lacking, CFD circulates
in plasma as the nonprocessed and inactive zymogen
incapable of supporting AP complement activation.10
Apart from their roles in the classic, lectin, and
alternative pathways of complement, C4b and C3b
attach to immune complexes or to target bacterial cells
through covalent binding; the opsonization of these
targets by C4b, C3b, or their further cleavage frag-
ments facilitates their transportation and clearance
through the reticuloendothelial system. Indeed, com-
plement activating immune complexes and opsonized
target cells interact with complement receptor 1 (CR1)
on human red blood cells via the bound C3b and C4b
fragments and are delivered rapidly to the liver and
spleen, where the target is handed over to the Kupffer
cells or to the marginal zone macrophages and den-
dritic cells and are phagocytosed11 (Table 1). This
transfer is mediated by complement receptors and
cell-derived proteases and facilitated by Fc receptors
present on the phagocytes. Mouse complement
receptor-related y (crry) on erythrocytes plays a similar
role as CR1 on red blood cells in human beings.
Binding of another receptor, complement receptor of
the immunoglobulin superfamily to C3b and its frag-
ment inactive C3b (iC3b) also has been shown to be
critical for the uptake of circulating immune complexes
by both mouse and human Kupffer cells.12 Apoptotic
cells bind C1q and ﬁx C3- and C4-derived fragments.
C1q plays an important role in the clearance of
apoptotic cells in the body because C1q bound to
syngeneic apoptotic cells not only activates the CP of
complement (Table 1), but also binds directly to
phagocytes.13 C1q deﬁciency indeed is associated with
a severe form of systemic lupus erythematosus with
overproduction of anti-DNA autoantibodies and accu-
mulation of apoptotic cells.13,14
iC3b and the ﬁnal cleavage product of C3b, C3d, bind
CR2 and play an important role in the cell-cycle control of
B cells15 (Table 1). It later was found that the main
function of the interaction of CR2 on B cells with antigen-
bound C3d is to lower the threshold for B-cell activation
by the B-cell antigen receptor.16 Immune complexes
including antigens and C3d cross-linked on B cells
through CR2 and B-cell receptors indeed are more
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Figure 2. The alternative pathway of complement activation. The AP is activated continuously in plasma by low-
grade hydrolysis of C3. The latter binds factor B to form a C3(H2O)B complex. CFD cleaves factor B to form the AP
initiation C3 convertase that cleaves C3 to C3b. The activation then is amplified by the covalent binding of a small
amount of C3b to hydroxyl groups on cell-surface carbohydrates and proteins of target cells such as bacterial cells.
This C3b binds factor B, to form the amplification loop C3 convertase C3bBb. The binding of properdin
(P) stabilizes this enzyme. C3 convertase enzymes cleave many molecules of C3, resulting in a positive feedback
amplification loop. C3b also binds to the C3 convertase, forming the C5 convertase enzyme C3b2Bb. The AP is
highly regulated to prevent nonspecific damage to host cells and limit the deposition of complement to the surface
of pathogens. This fine regulation occurs through a number of membrane-anchored and fluid phase regulators.
CFI (degrades C3b and C4b); CFH and CR1 both act as cofactors for factor I for C3b cleavage and favor the decay
of the C3 convertase of the AP; C4BP: C4b binding protein (beside inhibiting the classic and the lectin pathways of
complement, it also controls the alternative pathway by acting as a cofactor for factor I in the cleavage of C3b);
MCP binds C3b and C4b and has cofactor activity for both the classic and the alternative pathways.
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alone.17 B cells also express CR1, but much less is known
about the role of CR1-C3b signaling in B cells.16
Published studies would suggest that CR1 mediates
inhibitory signals in human B cells by blocking B-cell–
receptor–induced proliferation and inhibiting the differ-
entiation of B cells to plasmablasts and their immunoglo-
bulin production.16,18 Inactive C3b also binds the
leukocyte integrins CR3 and CR4 that belong to the
superfamily of adhesion molecules (Table 1). CR3 is
expressed on myeloid cells. It mediates the phagocytosis
of particles opsonized with iC3b. Some pathogens, such
as Staphylococcus epidermidis, directly bind CR3, with-
out the need of complement. CR4 is expressed both by
myeloid and lymphoid cells and it also is highly expressed
on tissue macrophages, where it represents an important
receptor for particles opsonized by iC3b (Table 1).C5 ACTIVATION AND THE TERMINAL PATHWAY
C5 Cleavage
C5 is the initiator of the effector terminal phase of the
complement system and shares the molecular structureconsisting of two chains—α and β, linked by disulﬁde
bonds, with C3 and C4, with the only difference being
that C5 does not contain an internal thio-ester bond.
The terminal phase is similar for the classical, lectin,
and alternative pathways. The incorporation of C3b in
the C3 convertases results in the formation of the C5
convertases: C3bBbC3b for the AP and C4bC2aC3b
for the CP and LP (Fig. 1). These C5 convertases
cleave C5 into C5a and C5b, ultimately resulting in the
formation of the multimeric MAC (C5b-9) (Fig. 1).19
Other factors of the coagulation and ﬁbrinolytic path-
way including thrombin; human factors XIa, Xa, and
IXa; and plasmin can cleave C5, independent of other
complement factors, in the so-called extrinsic comple-
ment pathway.20
C5a, and the other anaphylatoxin C3a that generates
from C3 cleavage, are potent bioactive molecules that
can act on a wide variety of cell types expressing their
high-afﬁnity binding transmembrane receptors C5aR
and C5L219,21 for C5a and C3aR for C3a.22 C5aR are
canonical G-protein–coupled signaling receptors; how-
ever, in contrast, C5L2 is unable to couple to G
proteins.23 All these receptors are expressed on
immune as well as nonimmune cells; however, C5L2
Complement activation and regulation 483is expressed at much lower levels compared
with C5aR.
C5a and C3a are potent inﬂammatory mediators
targeting a broad spectrum of immune and nonimmune
cells. By interacting with their G-protein–coupled
receptors C5aR and C3aR, C5a and C3a regulate
vasodilatation, increase the permeability of small blood
vessels, and induce contraction of smooth muscles.24
In macrophages, neutrophils and eosinophils C5a and
C3a can trigger an oxidative burst and in basophils can
stimulate the release of histamine. In eosinophils, C5a
and C3a regulate the production of eosinophil cationic
protein, their adhesion to endothelial cells, and their
migration. C5a is a powerful chemoattractant for
macrophages, neutrophils, activated B and T cells,
basophils, and mast cells,19,25 the latter of which also
migrate toward a C3a gradient (Table 1).
On the other hand, the other C5a receptor, C5L2,
may function as a decoy receptor regulating the
extracellular bioavailability of C5a, and so limiting
the proinﬂammatory response to C5a.26 It also may act
as a negative modulator of C5aR-mediated signal
transduction through the β-arrestin pathway.27 How-
ever, recent studies have suggested that C5L2 has a
proinﬂammatory role in experimental sepsis,28 allergic
asthma,29 and also may control the development of T-
helper 17 cells that are essential in asthma30 as well as
autoimmune arthritis.31
It should be noted that once plasma C5a and C3a are
released, plasma carboxypeptidases rapidly metabolize
them, by cleaving the C-terminal arginine to less-potent
forms: C5adesArg and C3adesArg.21 C5adesArg still
retains signaling activity at C5aR; however, it has
10-fold to 100-fold reduced afﬁnity for C5aR than
intact C5a.32 Thus, this metabolism of C5a by plasma
carboxypeptidases effectively limits the activity of C5a,
without eliminating all of its functions. Interestingly,
C5adesArg still retains high afﬁnity for C5L2,33 which
may enhance the proposed scavenger/decoy receptor
activity of C5L2. In contrast, C3aR does not recognize
the desarginate form (C3adesArg) of C3a.34Formation and Roles of the Terminal Membrane Attack
Complex (C5b-9)
In contrast to the early steps of complement activation,
assembly of the cytolytic C5b-9 (Fig. 1) on the cell
surface is a nonenzymatic process. It starts with the
interaction of C5b, released from C5 convertase
cleavage of C5, with C6. Binding of C7 to C5b6 leads
to the formation of a more stable trimeric complex,
C5b-7, which exposes transient lipid binding sites,
allowing its association with the cell membrane.
Interaction of C8 with C5b-7 results in the assembly
of the tetrameric complex C5b-8, which promotes
binding and polymerization of 10 to 16 molecules ofC9. The ﬁnal step of this process is the insertion of
C5b-9 MAC complex into the cell plasma membrane,
which causes cell death (Table 1). For a long time, the
damaging effect of MAC has been associated almost
exclusively to its cytolytic activity. Although this may
be true for some cell targets under special conditions,
as is the case of erythrocytes sensitized by antibodies
of well-deﬁned classes and subclasses and in sufﬁcient
numbers, the MAC does not appear, in general, to be
very efﬁcient, particularly on nucleated cells.
Nucleated cells are able to withstand MAC insertion
but they sustain sublethal injury, which leads to a
cascade of cellular events as discussed in the article by
Tamoko and Cybulsky.
Endothelial cells represent a potential target of
MAC, which exerts a number of noncytolytic
effects.19,35 The complex promotes inﬂammation
inducing the expression of adhesion molecules and
the release of chemokines and platelet activating factor,
which triggers the coagulation process, stimulating the
expression of tissue factor. This favors the shedding of
vesicles that support the formation of a prothrombinase
complex, and contributes to modify the vascular tone,
promoting the release of the vasodilator prostaglandin
I2 and the vasoconstrictor thromboxane A2 from
endothelial cells.
COMPLEMENT REGULATORS
The powerful effector functions of complement have
the potential to harm the host. The activation of CP and
LP is largely dependent on foreign material, but under
certain situations (eg, tissue ischemia and reperfusion),
both pathways can be activated and cause autologous
injury. More relevant to complement-related human
diseases, deposition of C3b via AP activation and
ampliﬁcation is nondiscriminatory and, if not properly
regulated, can damage host cells rapidly. Thus, it is
essential that activity be down-regulated on host cells
while efﬁcient activation is permitted on foreign
targets. Human beings and other mammals have deve-
loped a variety of both plasmatic and membrane-bound
inhibitory proteins to regulate the location and activity
of complement (Table 2).
C1 inhibitor (C1INH, also termed SERPING1)
irreversibly binds to and inactivates C1r and C1s of
the CP and MASP-1 and MASP-2 of the LP, thus
inhibiting the initiating steps of these activation path-
ways (Table 2, Fig. 3). Deﬁciency of C1INH results in
episodic angioedema. C1INH, in addition to its role as
a complement inhibitor, is the major inhibitor of factor
XIIa and kallikrein of the contact system. The lack of
inhibition of these enzymes by C1INH results in
inappropriate bradykinin generation. This in turn medi-
ates the increased vascular permeability characteristic
of angioedema.36
Table 2. Complement Regulatory Proteins in Human Beings and Their Functions
Regulator Function Location
C1 inhibitor (C1-INH) Inactivates C1r and C1s, MASP-1, and MASP-2 Plasma
MCP Cofactor for factor I–mediated cleavage of C3b and C4b Membrane-
bound
DAF Destabilizes C3/C5 convertases of the CP and AP (decay accelerating activity) Membrane-
bound
CR1 Decay accelerating activity as well as cofactor activity for factor I–mediated cleavage
of C3b and C4b
Membrane-
bound
C4 binding protein
(C4BP)
Binds to C4b; decay accelerating and cofactor activity Plasma
Factor H Binds to C3b; has decay accelerating activity of the AP C3 and C5 convertases and
cofactor activity
Plasma
Thrombomodulin Increases CFH cofactor activity, activates TAFI-mediated C3a and C5a inactivation Membrane-
bound
Factor I Degrades C3b and C4b aided by cofactors Plasma
CD59 Blocks the C9 association with C5b-8 to prevent C5b-9 formation on host cells Membrane-
bound
S-protein (vitronectin) Binds to C5b-7 and inhibits C9 polymerization Plasma
Clusterin (SP-40,40) Binds to C5b-7 and inhibits generation of C5b-9 Plasma
Abbreviation: TAFI, thrombin activatable fibrinolysis inhibitor.
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I (CFI) are the key plasma regulators of the AP of
complement (Table 2). If one of them is missing, or
totally dysfunctional, AP activation in plasma is
vigorous and leads to secondary complement deﬁ-
ciency via overconsumption of C3 and other comple-
ment components. CFI is a plasma serine protease that
is able to permanently inactivate C3b to iC3b byFigure 3. Mechanisms of complement regulation. (A) D
accelerates the dissociation of C3bBb (depicted) and C4bC
C3b and serves as a cofactor for CFI-mediated cleavag
inactivation. C1INH binds to C1r and C1s to inactivate the C
C9 association with C5b-8 and prevents MAC (C5b-9) formproteolysis, but needs a cofactor.37 iC3b then is
cleaved into further fragments (C3dg and C3c) by
CFI, again with the need for cofactor proteins.37 CFH
is one such cofactors.38,39 It is an abundant, single-
chain glycoprotein circulating at a concentration of
approximately 400 mg/L and is composed of 20 short
consensus repeat domains, each consisting of approx-
imately 60 amino acids. The major source of CFH isAF (or CFH, CR1) destabilizes C3 convertases and
2a. (B) Cofactor activity: MCP (or CFH, CR1) binds to
e and inactivation of C3b (or C4b). (C) C1 complex
1 enzyme complex. (D) MAC inhibition: CD59 inhibits
ation.
Complement activation and regulation 485the liver, but extrahepatic synthesis has been shown in
a variety of tissues including endothelial cells,40
glomerular mesangial cells,41 and, in rodents, podo-
cytes.39 CFH regulates AP activation by competing
with CFB in binding to C3b,42 by acting as a cofactor
for CFI in the C3b cleavage,38,39 and by decreasing the
stability of the C3bBb convertase complex, accelerat-
ing the dissociation to C3b and Bb (decay accelerating
activity) (Table 2). In addition to its regulatory activity
in plasma, CFH is practically the only molecule that is
involved in down-regulating AP activation on host
structures that lack other surface-bound regulators such
as basement membranes in kidney glomeruli.43 CFH
also contributes to the protection of cellular surfaces
such as endothelial cells thanks to its capability to bind
heparan sulfates and cell surface glycosaminoglycans
and the C3d part of C3b deposited on cell surfaces.44,45
Therefore, it is clear that CFH has a physiological
action both in the ﬂuid phase and at the cell surface,
particularly at the endothelial cell level. Deletion
mutagenesis studies have shown that regulation of
ﬂuid-phase C3 activation requires the N-terminal ﬁve
short consensus repeat domains46,47 in which both the
cofactor and decay-accelerating activities of CFH
reside. In contrast, targeting of the protein to cell
surfaces (surface recognition function) is mediated by
C-terminal domains.48
CFI also cleaves the C4b component of the CP and
LP C3 convertase C4bC2a in the presence of the
plasma cofactor C4b-binding protein (Table 2). Of
interest, C4b-binding protein also can favor C3b
inactivation, although to a lesser degree (Fig. 2).
Membrane-bound complement regulators include
membrane cofactor protein (MCP/CD46), decay-
accelerating factor (DAF/CD55), and CR1 (CD35)
(Table 2). MCP acts as a cofactor for C3b and C4b
cleavage by CFI (Fig. 3), but it only protects those cells
on which it is expressed.49 DAF accelerates the
dissociation of the C3bBb AP C3 convertase similarly
to CFH1,50 (Fig. 3). DAF also decreases the stability of
the C3 convertase of the classic and lectin pathways,
C4bC2a, by accelerating its dissociation to C4b and
C2a.51 CR1 on circulating cells mainly acts as an
immune adherence receptor to facilitate the removal
of C3b/C4b-opsonized immune complexes and patho-
gens from the circulation, but it also exerts complement
inhibitory activities. CR1 has cofactor activity for CFI-
mediated cleavage of C3b to iC3b, and thereafter to
C3c and C3dg, and of C4b. In addition, it exerts decay-
accelerating activities on the CP/LP and the AP C3
convertases (Table 2).51 More recently, the anticoagu-
lant endothelial transmembrane protein thrombomodu-
lin (THBD)52 has been shown to act also as a
complement regulator via two distinct mechanisms
(Table 2). THBD enhances CFI-mediated inactivation
of C3b on the cell surface in the presence of thecofactor CFH.53 In addition, THBD is a critical
cofactor for thrombin-mediated activation of the
plasma procarboxypeptidase thrombin activatable
ﬁbrinolysis inhibitor.52,54 Active thrombin activatable
ﬁbrinolysis inhibitor inhibits ﬁbrinolysis by removing
lysine residues from modiﬁed ﬁbrinogen, but also
des-arginates and inactivates the anaphylatoxins C3a
and C5a.52,55
In addition, the terminal MAC is regulated closely
both in ﬂuid phase and on cell membranes (Table 2,
Fig. 3). Vitronectin, also known as protein S, is one of
these regulators, which binds preferentially to C5b-7
and interacts with C9 to form SC5b-9, inhibiting its
polymerization.56 Clusterin (Table 2) is another com-
plement regulator that not only acts at the level of C7 as
a component of C5b-7, preventing the insertion of this
complex into the cell membrane, but also binds to C8
and to C9, inhibiting the polymerization of C9.57 These
two inhibitors do not interfere with the full assembly of
the complex, which, however, contains a substantially
lower number of C9 molecules than MAC.
The CFH-related protein 1 (CFHR-1) has been
reported as a novel regulator58 that inhibits the C5
convertase of the AP and binds to C5 and C5b-6,
preventing the formation of MAC. A more recent study,
however, indicated that CFHR1 along with CFHR2 and
CFHR5 might act as complement activators through the
formation of both homodimers and heterodimers.
Dimerization confers avidity for tissue-bound comple-
ment fragments and enables these proteins to compete
efﬁciently with CFH for ligand binding.59
CD59 is the key regulator of the terminal pathway
(Table 2, Fig. 3). It inhibits C9 association with C5b-8
to prevent C5b-9 formation. Both CD59 and DAF are
anchored to cell membranes by a glycosyl phosphati-
dylinositol molecule. Somatic mutations in the phos-
phatidylinositol glycan complementation class A gene
in red blood cells3 result in a rare clonal disorder called
paroxysmal nocturnal hemoglobinuria. As a result of
defective phosphatidylinositol glycan complementation
class A function, affected red cells lack all glycosyl
phosphatidylinositol–linked membrane proteins to
autologous complement-mediated lysis with conse-
quent hemolytic anemia.
COMPLEMENT AND ADAPTIVE IMMUNITY
Immune cells, including T cells and antigen-presenting
cells, produce complement products that have impli-
cations for organ transplantation and autoimmune
diseases60,61 (see the article by Cravedi and Heeger).
Cognate T-cell––antigen-presenting cell interactions
that result in T-cell activation are associated with the
up-regulation and release of the AP complement
components C3, CFB, and CFD by both cell types.61
The resultant activation products C3a and C5a bind to
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strength of the induced T-cell response.62 C3aR and
C5aR signaling in T cells enhance T-cell proliferation
and diminish T-cell apoptosis. The immune cell–
derived and locally produced C3a and C5a also bind
to C3aR/C5aR on antigen-presenting cells, inducing
the release of cytokines (eg, interleukin-12 and inter-
leukin-13) and up-regulating costimulatory molecules
such as B7, further amplifying the immune response
and directing T-cell phenotype toward interferon-γ–
producing T-helper 1 immunity.61
More recent studies have shown that natural regu-
latory T cells express C3aR and C5aR and that
signaling through these receptors inhibits natural reg-
ulatory T-cell function.63 Indeed, genetic and pharma-
cologic blockade of C3aR/C5aR signal transduction in
mouse natural regulatory T cells augmented their
suppressive function in vitro and in vivo, abrogated
autoimmune colitis, and prolonged allogeneic skin
allograft survival.63 Another study documented that
when signals from C3aR and C5aR were blocked both
in mouse and human CD4 T cells, this favored their
transformation to induced Foxp3þ regulatory T cells in
the presence of transforming growth factor β.64 The
resulting induced Foxp3þ regulatory T cells exerted
robust suppression on T-cell proliferation, had
enhanced stability, and suppressed ongoing autoim-
mune disease when injected in mice with experimental
autoimmune encephalomyelitis.64
Complement-dependent effects on alloreactive
T-cell immunity regulate the phenotypic expression
of immune-mediated injury in animal models. Further
conﬁrming a key role for C5a–C5aR interactions as
pathogenic in transplant rejection are data indicating
that C5aR blockade prolongs kidney transplant sur-
vival in rodents.65 This improved outcome is associ-
ated with an abrogation of intragraft mononuclear cell
inﬁltration and a diminution in T-cell alloreactivity. In
addition, mice deﬁcient in either or both C5aR and
C3aR develop less autoimmunity and are resistant to
experimental allergic encephalomyelitis.62 Taken
together, these results indicate that complement is
a physiologically important regulator of alloreactive
T-cell immunity and in autoimmunity.
COMPLEMENT IN THE KIDNEY
Because of its highly specialized function, the kidney
is subject to signiﬁcant stress from exogenous factors
(eg, pathogens, toxins, and cytokines ﬁltered from the
bloodstream). Consequently, renal function is depend-
ent on a ﬁnely calibrated immune response including
proper complement activation and regulation.
Although traditional thinking focuses on liver-
derived serum complement as a principal pathogenic
mediator of kidney injury, it is now abundantly clearthat complement components are produced by paren-
chymal kidney cells as well.66
A comprehensive range of complement genes are
expressed in the kidney.67 Some complement compo-
nents that are produced primarily at extrahepatic sites
(eg, C1q and CFD) are detected strongly in glomeruli.
C1q, which is synthesized mainly in mononuclear
phagocytes and epithelial cells, has been suggested to
play an important role in the clearance of immune
complexes and apoptotic bodies in the kidney.68,69
Local expression of C1q could have a kinetic advant-
age over deposition of a circulating component. On the
other hand, CFD, which is synthesized primarily by
adipocytes, participates in the cleavage of CFB and
thus contributes to AP function.
At variance with the glomerulus, tubules more
strongly express the main components of complement
synthesized in the liver (C2, C4, C3, and factor B).67
The glomerulus, because of its constant exposure to
blood, is continuously in contact with plasma liver-
derived complement factors, whereas the tubulointersti-
tium of the kidney is much more restricted in its access
to circulating complement proteins. This area of the
kidney has adapted to make its own complement
proteins, possibly because of exposure to microorgan-
isms ascending through the urinary tract. Thus, cluster-
ing of the components of the activation pathways in the
tubule may act as a front-line defense against pathogens.
Four types of resident kidney cells are capable of
synthesizing complement proteins when grown in
tissue culture: glomerular epithelial cells, glomerular
endothelial cells, mesangial cells, and proximal tubular
cells.70–74 Secretion of C3 by such cells occurs
spontaneously and may approach levels comparable
with those produced by cultured hepatoma cells.74 In
contrast, the expression of C4 often is detected weakly
in cultured cells, even though the signal derived from
tissue messenger RNA may be strong. This discrep-
ancy between in vivo and in vitro expression may be
owing to rapid loss of ability to synthesize C4 in vitro,
as noticed in monocyte studies.75 Factor B also is
detected weakly in vitro. However, many stimulators,
including cytokines, growth factors, immune com-
plexes, serum proteins, and human cytomegalovirus,
can increase the expression of C3, C4, and factor B by
cultured cells.66
Numerous factors have been shown to regulate the
production of complement by renal cells.66 The effects
of some of these signals are tissue-speciﬁc, and the
response may vary even with different cell types in the
same tissue. For example, interleukin-1 may induce a
two-fold to three-fold increase in the renal expression of
C2 in mice, but has no effect on hepatic synthesis of
C2.76 Another example is tumor necrosis factor-α,
which regulates the transcription of C3 in glomerular
endothelial cells,74 but has no such effect in glomerular
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interferon-γ appear to play a major role in regulating
the production of C3 and C4 by proximal tubular cells.70
Furthermore, interferon-γ induces changes in renal gene
transcription whereas in hepatocytes it may act at the
level of RNA translation to increase local complement
synthesis.73 This local variation in the regulation of
complement may allow ﬁne-tuning of tissue levels
expressed without alteration of circulating levels.
The transmembrane receptors for C3a and C5a
(C3aR and C5aR), and the integral membrane CRs
for C3b, iC3b, and C3dg, are expressed outside the
kidney, particularly in cells of hematopoietic and
immune lineage. These are important in renal injury
through their inﬁltration of the kidney and/or by
affecting kidney-directed immune responses. There is
mounting evidence that intrinsic glomerular and tubu-
lar cell C3aR and C5aR expression and activation also
can affect renal injury.77,78 CR1 on podocytes and CR3
and CR4 in kidney dendritic cells have functions that
remain poorly deﬁned. These can be engaged by C3
and C5 activation products derived from systemic and
local pools in renal injury. The deposition of the MAC
complex, C5b-9 on glomeruli and tubules of diseased
kidney, has led to investigation of the activity of the
complex on renal cells. In mesangial and tubular cells,
the complex has a dual effect. On one hand, C5b-9
stimulates both cell types to release cytokines and
collagen, which cause tissue ﬁbrosis,79 and on the
other hand it is able to induce or enhance apoptosis.80
In addition to the complement activation pathway
components, a number of complement regulatory
proteins, particularly membrane-bound proteins, are
synthesized within the kidney. These include DAF,
MCP, CR1, and CD59. The distribution of these
inhibitory proteins in normal and diseased kidneys
has been studied comprehensively.81–83 These studies
have shown considerable variation in the level of
membrane regulators depending on cell type, suggest-
ing that complement is regulated by distinct inhibitors
within different sections of the kidney.84 Studies of
human and mouse kidney have shown ubiquitous
expression of CD59 on all major cell types within
the kidney. DAF is found mostly on podocytes,
endothelial cells, and in the juxtaglomerular apparatus.
MCP is expressed throughout human renal tissues, but
rodents do not normally express MCP beside sperma-
tozoa. The rodent-speciﬁc complement regulator Crry
is expressed ubiquitously in the kidney and is consid-
ered a functional homolog of human MCP. In human
kidney, CR1 is restricted mostly to podocytes,
although similar to MCP, rodents only have limited
expression of CR1, which is generated by alternative
splicing from the Cr1/2 gene.84
The renal tubule is relatively deﬁcient in comple-
ment regulators, helping to explain the vulnerability ofthe renal tubule to complement attack.83 Cell-
associated regulators at the C3 level, DAF CR1, and
MCP are hardly detectable on the apical membrane of
proximal tubular cells.66 Conversely, human proximal
tubular cells produce CFH,85 the main soluble inhibitor
of the AP. In addition, we found that CFH binds to
heparan sulfate residues on human proximal tubular
cell surface through its C-terminal domain.86 Impor-
tantly, surface-bound CFH limited C3 and C5b-9
deposits on the tubular cell surface, which indeed were
enhanced in the presence of antibodies blocking either
the N-terminal cofactor site or the C-terminal mem-
brane binding site of CFH.86
The expression of regulatory molecules is up-
regulated during the activation of complement,66 as
occurs in a number of forms of renal disease.66,82 Not
surprisingly, overexpression of complement regulatory
proteins in mice markedly ameliorated nephrotoxic
serum nephritis.87 This indicates that complement
regulatory proteins play a protective role against
complement-mediated renal injury. The kidney there-
fore has a set of positive and negative internal controls
with the ability to inﬂuence complement activation on
the renal structures.
Complement activation affects a broad range of
renal diseases moving from antibody-mediated glomer-
ular diseases to thrombotic microangiopathies, pro-
gressive kidney diseases, and ischemia/reperfusion
injury. A brief overview of the involvement of comple-
ment in kidney diseases that is discussed in detail in
other articles in this issue is given below (Table 3).COMPLEMENT IN KIDNEY DISEASES
Glomerulopathies
One of the fundamental protective actions of comple-
ment is the clearance of invasive pathogens and the
removal of immune complexes and cell debris. This is
evident in individuals with inherited C3 deﬁciency who
develop recurrent bacterial infections and immune
complex glomerulonephritis.3 In contrast to its physio-
logic function, complement activation leads to inﬂam-
mation in several types of glomerulonephritis, such as
systemic lupus erythematosus, IgA nephropathy, Good-
pasture syndrome (anti–glomerular basement mem-
brane [GBM] glomerulonephritis), antineutrophil
cytoplasmic autoantibody (ANCA)-induced glomerulo-
nephritis, and membranous nephropathy.77,84
Anti-GBM–induced glomerulonephritis is character-
ized by immune complex deposition along the GBM.
Many studies have shown that the complement system
affects anti-GBM glomerulonephritis in human beings
by amplifying antibody-mediated injury through CP
and enhancing the inﬂammatory response through C5
activation.88 In the experimental model of this disease
Table 3. Summary of the Main Complement-Associated Renal Diseases
Disease Pathogenesis
Complement
Pathway
Lupus nephritis Anti-DNA antibodies, accumulation of apoptotic cells CP
Post-streptococcal glomerulonephritis Antibody mediated, circulating or planted antigens CP
Goodpasture syndrome Anti-GBM antibodies CP
IgA nephropathy Deposition of polymeric IgA CP/AP
ANCA-associated vasculitis Antibodies directed against neutrophil components CP/AP
Membranous nephritis Antibody-antigen complexes subepithelially CP AP/LP
MPGN I Immune complexes, C3NeF, complement gene mutations CP/AP
C3 glomerulopathies C3NeF, complement gene mutations AP
STEC-HUS Shiga-toxin mediated endothelial injury/activation AP
aHUS Complement gene mutations, anti-CFH antibodies AP
Tubulointerstitial injury in proteinuric progressive
glomerulopathies
Proteins (including complement components) abnormally
ultrafiltered by the glomeruli
AP
I/R injury Ischemic tissue injury, oxygen radicals AP/LP
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C3, or deﬁciency of C4 reduced renal disease. Subse-
quent studies showed that loss of DAF, Crry, CFH, and/
or CD59 all exacerbated anti-GBM glomerulonephritis
in mice, highlighting the relevance of complement
control mechanisms in autoimmune kidney injury.84
Complement has been shown to play a key role in
experimental (ANCA)-associated glomerulonephri-
tis.89 Mice depleted of C3 with cobra venom factor
and mice lacking C5 or treated with a C5 inhibitory
antibody were protected from disease induced by
injection of antimyeloperoxidase or anti–proteinase
3 antibodies. In the same model, no disease was seen
in mice lacking CFB, whereas C4-deﬁcient mice
showed symptoms of ANCA-associated glomerulo-
nephritis, which implicates AP activation and excludes
a role for the CP and LP.89 The mechanistic link
between ANCA-induced neutrophil activation and
initiation of the AP complement system remains to
be elucidated, and whether anticomplement therapy
might be effective clinically has yet to be established.
Membranous nephropathy (MN) is another form of
immune-mediated glomerular injury in which immune
complexes of immunoglobulins and complement accu-
mulate in a granular pattern along the outer side of the
GBM, leading to glomerular visceral epithelial cell
detachment90 (see the articles by Beck et al and Takano
and Cybulsky). Seminal studies have identiﬁed several
autologous antigens that are targets of antibody
response in MN. In most patients with the idiopathic
autoimmune form of MN, the autoantibodies are of the
IgG4 and IgG1 type and are directed to the phospho-
lipase A2-receptor.90,91 These antibodies may affect
glomerular visceral epithelial cells directly through
interaction with the phospholipase A2-receptor.
The role of complement has been established clearly
in experimental MN. Indeed, complement activationand local formation of C5b-9 is a prerequisite for the
development of glomerular injury in rats with passive
Heymann nephritis, an experimental model of MN, as
documented by studies showing that complement
inhibition with recombinant CR1 led to a reduction
in proteinuria in this model.92
In human secondary MN, especially the forms
associated with lupus, most studies found abundant
C1q, whereas the role of the classic pathway in primary
MN is uncertain because renal C1q deposits rarely are
found. This ﬁts with the IgG subclasses in immune
deposits, predominantly IgG1 and IgG3 in secondary
MN and predominantly poorly complement-ﬁxing
IgG4 in primary MN. On the other hand, C3, C4,
CFB, MBL, and C5b-9 typically are present and co-
deposited with IgG, suggesting that the lectin and the
alternative pathways of complement activation could
play a role (see articles in this issue by Ma et al and
Takano and Cybulsky).
Inappropriate activation of the AP of complement
system as a result of inefﬁcient inhibition may lead to
prolonged tissue damage and glomerular diseases. This
mechanism recently was shown to underlie the Escher-
ichia coli–associated and atypical forms of hemolytic
uremic syndrome (aHUS).93 Sixty percent of aHUS
cases are related to mutations in genes encoding
complement regulatory proteins, CFH, MCP, CFI,
and THBD, the alternative pathway C3 convertase
components C3 and CFB, or inhibitory anti-CFH
autoantibodies.94 Patients with combined mutations in
2 or 3 different complement genes also have been
reported underlying the complexity of aHUS
genetics.95
Similar to HUS, idiopathic forms of membranoproli-
ferative glomerulonephritis (MPGN) are associated
commonly with defective complement regulation. A
recent immunoﬂuorescence-based classiﬁcation approach
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deposits, known as C3 glomerulopathies, and character-
ized by defective control of the AP of complement from
MPGN type I with deposits of immunoglobulin and
complement and characterized by activation of the CP by
antigen-antibody immune complexes.96 However, such
distinction is not accepted universally and evidence is
accumulating that some cases of MPGN with C3 and
immunoglobulin deposits also may involve abnormalities
of AP regulation.97 C3NeF, an autoantibody stabilizing
the AP C3-convertase, is found in 50% to 75% of
patients with C3-glomerulopathies, but also is found in
approximately half of patients with MPGN I. Auto-
antibodies against CFH and CFB and complement gene
mutations also have been reported.Tubulointerstitial Injury in Progressive Kidney Diseases
Progressive glomerular diseases invariably are accom-
panied by tubulointerstitial damage, the extent of
which is linked closely to an adverse renal outcome.
The various proteins of the complement system are
among the proteins appearing in the urine in non-
selective glomerular proteinuria, leading to intratubular
deposition of C3 and of C5b-9, and their activation
also has been proposed to contribute to tubulointer-
stitial damage98 via cytotoxic, proinﬂammatory, and
ﬁbrogenic effects.
Abnormal C3 and C5b-9 staining in proximal tubular
cells and along the brush border is a long known feature
in chronic proteinuric diseases.98 Investigation using
proteinuric models of glomerular injury showed less
tubulointerstitial damage in complement-depleted rats
and/or C6-deﬁcient rats, or upon treatment with
complement-inhibitory molecules.14 Evidence subse-
quently was provided that C3 and ultraﬁltered plasma
proteins co-localized to proximal tubular cells that were
exposed to ﬁltered protein overload in rats with remnant
kidney before the accumulation of monocyte/macro-
phages in the interstitium.14,98 Treatment with an
angiotensin-converting enzyme inhibitor limited the
excess load of both C3 and plasma proteins in proximal
tubular cells and prevented the recruitment of inﬂam-
matory cells. In mice with protein overload–induced
proteinuria, complement appeared to be an important
effector of interstitial mononuclear cell inﬁltration and
ﬁbrogenesis, as shown by signiﬁcant attenuation of
injury in C3-deﬁcient mice.99
Renal tubular cells synthesize C3 and other comple-
ment factors and exposure of cultured proximal tubular
cells to total serum proteins up-regulated C3 messenger
RNA expression and protein biosynthesis. Therefore,
both excess ultraﬁltration and protein-overload–
induced proximal tubular cell synthesis of complement
components could underlie complement-mediated
injury in chronic proteinuric renal diseases.98For determination of the injurious role of plasma-
derived C3, as opposed to tubular cell–derived C3, C3-
deﬁcient kidneys were transplanted into wild-type
mice99 before inducing protein-overload proteinuria.
Protein overload led to the development of glomerular
injury, accumulation of C3 in podocytes and proximal
tubules, and tubulointerstitial changes. Conversely,
when wild-type kidneys were transplanted into C3-
deﬁcient mice, protein overload led to a milder disease
and abnormal C3 deposition was not observed.99 These
data suggest that ultraﬁltered C3 contributes more to
tubulointerstitial damage induced by protein overload
than locally synthesized C3.Ischemia-Reperfusion Injury
In most organs, ischemia-reperfusion (I/R) injury is
initiated by natural antibodies and activation of the CP
of complement, but in the kidney immunoglobulins and
CP activation do not appear to play a major role because,
at variance with other organs, antibodies are not depos-
ited in the kidney after I/R100 (see articles by Quigg et al
and Thurman et al). The AP appears to be involved, as
documented by ﬁndings that C3- or CFB-deﬁcient mice
are resistant to renal I/R injury, whereas C4 deﬁciency is
not protective.101 Additional studies documented that
murine C3-deﬁcient kidneys are protected from posti-
schemic damage after transplantation into syngeneic
murine recipients with normal C3, whereas wild-type
kidneys developed I/R injury upon transplantation into
syngeneic C3-deﬁcient recipients. These data indicate
that kidney-derived C3, rather than circulating C3, drives
the development of kidney I/R injury, at least in rodents.
Small interfering RNA–induced down-regulation of the
C5a anaphylatoxin receptor C5aR or administration of a
C5aR antagonist prevented neutrophil inﬁltration and
limited postischemic kidney injury in rodents, support-
ing a role for C5a–C5aR interactions in the pathogenesis
of I/R injury in the kidney.61
All of the earlier-mentioned studies have been
performed in rodents. Limited information is currently
available from human beings and larger animals. In a
recent study in swine, renal I/R injury resulted in the
formation of C4d/C1q, C54/MBL, and MBL/MASP-2
deposits. Infusion of C1-inhibitor reduced complement
deposits and inﬁltrating inﬂammatory leukocytes and
limited tubular damage, which suggests that the CP/LP
pathways of complement might contribute to kidney
I/R injury.102CONCLUSIONS
The involvement of the complement system in renal
diseases is complex. There are multiple mechanisms
of complement activation, and activation generates
multiple biologically active fragments. Complement
M. Noris and G. Remuzzi490is involved in the resolution of injury as well; part of
the complement activation seen in glomerulonephritis
is the normal reaction to remove immune complexes
and damaged cells from the glomerulus.
Eculizumab now has been used in dozens of patients
with aHUS, MPGN, or at risk for humoral allograft
rejection. Although these conditions are rare in the
population, their studies have provided important
insight to the pathogenesis of complement-mediated
renal tissue injury as well as new understanding of
mechanisms of action of complement regulatory pro-
teins. These advances also have fueled many efforts to
develop new targeted complement inhibitors and it is
likely that in the near future complement-inhibitory
drugs will be used in patients with more common types
of renal diseases.REFERENCES
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